CYP19A1 and breast cancer: We look at the complete pathological response and relapse-free survival profile for all BC subtypes treated with chemotherapy agents (Taxane, Ixabepilone, FAC (Fluorouracil, Adriamycin, and Cytoxan), CMF (cyclophosphamide, methotrexate, and 5 fluorouracil (also known as 5FU)), FEC (5 fluorouracil (also known as 5FU), epirubicin, and cyclophosphamide), Anthracycline), and endotherapy drugs (Tamoxifen, Aromatase inhibitor), and any anti−HER2 therapy (Trastuzumab, Lapatinib).